The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On May 10, 2012, the European Commission issued a conditional marketing authorization valid throughout the European Union for pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (NHL). Pixantrone is a cytotoxic aza-anthrac...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Péan, Elias, Flores, Beatriz, Hudson, Ian, Sjöberg, Jan, Dunder, Kristina, Salmonson, Tomas, Gisselbrecht, Christian, Laane, Edward, Pignatti, Francesco
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2013
Aiheet:
Regulatory Issues: EMA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3662855/
https://ncbi.nlm.nih.gov/pubmed/23615696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0020
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia